Home › Companies › Coherus Oncology, Inc. › 2025-2026
Compiled from SEC Form N-PX filings and Coherus Oncology, Inc.’s Form 8-K, filed 2026-06-01 (Item 5.07 on EDGAR). Page generated 04 October 2026.
Proxy season: 2025-2026
Explore Coherus Oncology, Inc. in the interactive database Compare manager voting policies
These tallies are Coherus Oncology, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-01 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Dennis M. Lanfear | 82,524,713 | -- | -- | 6,482,243 | 35,559,085 | Majority: yes |
| Elect Director: Mats L. Wahlström | 81,177,717 | -- | -- | 7,829,239 | 35,559,085 | Majority: yes |
| Proposal 2. The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026. | 121,137,511 | 1,481,497 | 1,947,033 | -- | 0 | Majority: yes |
| Proposal 3. The Company's stockholders approved a non-binding, advisory resolution to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote). | 73,322,772 | 10,862,168 | 4,822,016 | -- | 35,559,085 | Majority: yes |
| Proposal 4. The Company's stockholders approved the reduction in the exercise price of certain outstanding stock options. | 45,996,610 | 45,362,110 | 391,335 | -- | 0 | Majority: yes |
| Proposal 5. The Company's stockholders approved an increase in the number of shares of common stock reserved for issuance under the Amended and Restated 2014 Equity Incentive Award Plan. | 59,507,788 | 24,853,379 | 4,645,789 | -- | 35,559,085 | Majority: yes |
This meeting is also recorded here as 2026-05-27; both records come from the same filing, so the date should be checked against it.
Source: Coherus Oncology, Inc., Form 8-K, filed with the SEC on 2026-06-01 — read the filing on EDGAR.
Each item below shows how the 127 asset managers that disclosed a Coherus Oncology, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 12 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
Coherus Oncology, Inc.’s own tally for this item (“Proposal 3. The Company's stockholders approved a non-binding, advisory resolution to approve the compensation of the Company's named executive officers (a "Say-on-Pay" vote).”): 73,322,772 for, 10,862,168 against, per its Form 8-K filed 2026-06-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 154,249,900 outstanding shares: 47.5% for, 7% against (54.6% of the company cast a for/against vote).
The 126 asset managers below cast 94% of the shares they voted on this item FOR (46,404,072 for, 2,869,689 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Janus Henderson | 17,142,856 | 0 | 0 | 0 | For |
| Vanguard | 5,185,366 | 24 | 12 | 0 | For |
| BlackRock | 3,488,436 | 1 | 0 | 0 | For |
| Kohlberg Kravis Roberts & Co. L.P. | 3,036,076 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,341,450 | 0 | 0 | 0 | For |
| Charles Schwab | 2,316,191 | 0 | 0 | 0 | For |
| C WorldWide Asset Management Fondsmaeglerselskab A/S | 0 | 1,928,464 | 0 | 0 | Against |
| Fidelity | 1,883,688 | 0 | 0 | 0 | For |
| Samsara BioCapital, LLC | 1,714,286 | 0 | 0 | 0 | For |
| State Street | 1,145,548 | 5,311 | 0 | 0 | For |
| Two Sigma | 973,341 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 900,000 | 0 | 0 | 0 | For |
| NOMURA INVESTMENT MANAGEMENT BUSINESS TRUST | 900,000 | 0 | 0 | 0 | For |
| Northern Trust | 651,631 | 3,169 | 0 | 0 | For |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0 | 441,000 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 441,000 | 0 | 0 | Against |
| AQR | 425,732 | 0 | 0 | 0 | For |
| PANAGORA ASSET MANAGEMENT INC | 333,791 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 325,306 | 0 | 0 | 0 | For |
| STRS OHIO | 324,000 | 0 | 0 | 0 | For |
| Goldman Sachs | 290,086 | 0 | 0 | 0 | For |
| Invesco | 264,148 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 253,140 | 0 | 0 | 0 | For |
| Informed Momentum Co LLC | 247,338 | 0 | 0 | 0 | For |
| Equitable | 222,302 | 0 | 0 | 0 | For |
Showing the 25 largest of 126 asset managers. See all 126 in the interactive database.
Combines 7 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
Coherus Oncology, Inc.’s own tally for this item (“Elect Director: Dennis M. Lanfear”): 82,524,713 for, 6,482,243 withheld, per its Form 8-K filed 2026-06-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 154,249,900 outstanding shares: 53.5% for, 4% withheld (58% of the company cast a for/withheld vote).
The 41 asset managers below cast 100% of the shares they voted on this item FOR (11,778,798 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,462,755 | 0 | 14,565 | 0 | For |
| Fidelity | 1,875,742 | 0 | 0 | 0 | For |
| BlackRock | 1,461,890 | 0 | 0 | 0 | For |
| Charles Schwab | 1,158,081 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 900,000 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 441,000 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 253,140 | 0 | 0 | 0 | For |
| Invesco | 241,418 | 0 | 0 | 0 | For |
| Equitable | 88,662 | 0 | 133,640 | 0 | Abstain |
| AQR | 126,537 | 0 | 0 | 0 | For |
| Goldman Sachs | 111,017 | 0 | 0 | 0 | For |
| TIAA | 95,235 | 0 | 0 | 0 | For |
| Lincoln Financial | 76,805 | 0 | 0 | 0 | For |
| Northern Trust | 63,646 | 0 | 0 | 0 | For |
| Global X | 48,708 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 47,435 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 41,829 | 0 | 0 | 0 | For |
| Pacific Life | 40,030 | 0 | 0 | 0 | For |
| Brighthouse | 34,326 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 31,660 | 0 | 0 | 0 | For |
| John Hancock | 24,919 | 0 | 0 | 0 | For |
| ProShares | 21,717 | 0 | 0 | 0 | For |
| Voya | 16,971 | 0 | 0 | 0 | For |
| DWS | 15,322 | 0 | 0 | 0 | For |
| SEI | 14,800 | 0 | 0 | 0 | For |
Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.
Combines 8 wordings of this item as funds reported it.
91% Majority: yes · of votes cast
Coherus Oncology, Inc.’s own tally for this item (“Elect Director: Mats L. Wahlström”): 81,177,717 for, 7,829,239 withheld, per its Form 8-K filed 2026-06-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 154,249,900 outstanding shares: 52.6% for, 5% withheld (58% of the company cast a for/withheld vote).
The 41 asset managers below cast 100% of the shares they voted on this item FOR (10,829,691 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,467,475 | 0 | 16 | 0 | For |
| Fidelity | 1,875,742 | 0 | 0 | 0 | For |
| BlackRock | 1,461,890 | 0 | 0 | 0 | For |
| Charles Schwab | 1,158,081 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 0 | 900,000 | 0 | Abstain |
| BRIDGEWAY FUNDS INC | 441,000 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 253,140 | 0 | 0 | 0 | For |
| Invesco | 241,418 | 0 | 0 | 0 | For |
| Equitable | 88,662 | 0 | 133,640 | 0 | Abstain |
| AQR | 126,537 | 0 | 0 | 0 | For |
| Goldman Sachs | 111,017 | 0 | 0 | 0 | For |
| TIAA | 95,235 | 0 | 0 | 0 | For |
| Lincoln Financial | 76,805 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 63,646 | 0 | Abstain |
| Global X | 48,708 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 47,435 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 41,829 | 0 | 0 | 0 | For |
| Pacific Life | 40,030 | 0 | 0 | 0 | For |
| Brighthouse | 34,326 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 31,660 | 0 | 0 | 0 | For |
| John Hancock | 24,919 | 0 | 0 | 0 | For |
| ProShares | 21,717 | 0 | 0 | 0 | For |
| Voya | 16,971 | 0 | 0 | 0 | For |
| DWS | 15,322 | 0 | 0 | 0 | For |
| SEI | 14,800 | 0 | 0 | 0 | For |
Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.
Combines 3 wordings of this item as funds reported it.
71% Majority: yes · of votes cast
Coherus Oncology, Inc.’s own tally for this item (“Proposal 5. The Company's stockholders approved an increase in the number of shares of common stock reserved for issuance under the Amended and Restated 2014 Equity Incentive Award Plan.”): 59,507,788 for, 24,853,379 against, per its Form 8-K filed 2026-06-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 154,249,900 outstanding shares: 39% for, 16% against (54.7% of the company cast a for/against vote).
The 41 asset managers below cast 81% of the shares they voted on this item FOR (9,613,299 for, 2,324,065 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,467,420 | 9,888 | 12 | 0 | For |
| Fidelity | 1,875,742 | 0 | 0 | 0 | For |
| BlackRock | 1,461,890 | 0 | 0 | 0 | For |
| Charles Schwab | 1,158,081 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 0 | 900,000 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 441,000 | 0 | 0 | Against |
| Simplify Exchange Traded Funds | 253,140 | 0 | 0 | 0 | For |
| Invesco | 0 | 241,418 | 0 | 0 | Against |
| Equitable | 88,662 | 133,640 | 0 | 0 | Against |
| AQR | 0 | 126,537 | 0 | 0 | Against |
| Goldman Sachs | 111,017 | 0 | 0 | 0 | For |
| TIAA | 0 | 95,235 | 0 | 0 | Against |
| Lincoln Financial | 0 | 76,805 | 0 | 0 | Against |
| Northern Trust | 0 | 63,646 | 0 | 0 | Against |
| Global X | 48,708 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 0 | 47,435 | 0 | 0 | Against |
| Bridge Builder Trust | 41,829 | 0 | 0 | 0 | For |
| Pacific Life | 40,030 | 0 | 0 | 0 | For |
| Brighthouse | 0 | 34,326 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 31,660 | 0 | 0 | 0 | For |
| John Hancock | 0 | 24,919 | 0 | 0 | Against |
| ProShares | 0 | 21,717 | 0 | 0 | Against |
| Voya | 0 | 16,971 | 0 | 0 | Against |
| DWS | 0 | 15,322 | 0 | 0 | Against |
| SEI | 14,800 | 0 | 0 | 0 | For |
Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.
Combines 3 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
Coherus Oncology, Inc.’s own tally for this item (“Proposal 2. The Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026.”): 121,137,511 for, 1,481,497 against, per its Form 8-K filed 2026-06-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 154,249,900 outstanding shares: 79% for, 1.0% against (79% of the company cast a for/against vote).
The 41 asset managers below cast 99.9% of the shares they voted on this item FOR (11,937,369 for, 3 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 4,477,313 | 3 | 5 | 0 | For |
| Fidelity | 1,875,742 | 0 | 0 | 0 | For |
| BlackRock | 1,461,890 | 0 | 0 | 0 | For |
| Charles Schwab | 1,158,081 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 900,000 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 441,000 | 0 | 0 | 0 | For |
| Simplify Exchange Traded Funds | 253,140 | 0 | 0 | 0 | For |
| Invesco | 241,418 | 0 | 0 | 0 | For |
| Equitable | 222,302 | 0 | 0 | 0 | For |
| AQR | 126,537 | 0 | 0 | 0 | For |
| Goldman Sachs | 111,017 | 0 | 0 | 0 | For |
| TIAA | 95,235 | 0 | 0 | 0 | For |
| Lincoln Financial | 76,805 | 0 | 0 | 0 | For |
| Northern Trust | 63,646 | 0 | 0 | 0 | For |
| Global X | 48,708 | 0 | 0 | 0 | For |
| CLEARWATER INVESTMENT TRUST | 47,435 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 41,829 | 0 | 0 | 0 | For |
| Pacific Life | 40,030 | 0 | 0 | 0 | For |
| Brighthouse | 34,326 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 31,660 | 0 | 0 | 0 | For |
| John Hancock | 24,919 | 0 | 0 | 0 | For |
| ProShares | 21,717 | 0 | 0 | 0 | For |
| Voya | 16,971 | 0 | 0 | 0 | For |
| DWS | 15,322 | 0 | 0 | 0 | For |
| SEI | 14,800 | 0 | 0 | 0 | For |
Showing the 25 largest of 41 asset managers. See all 41 in the interactive database.
Combines 2 wordings of this item as funds reported it.
50.3% Majority: yes · of votes cast
Coherus Oncology, Inc.’s own tally for this item (“Proposal 4. The Company's stockholders approved the reduction in the exercise price of certain outstanding stock options.”): 45,996,610 for, 45,362,110 against, per its Form 8-K filed 2026-06-01 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 154,249,900 outstanding shares: 30% for, 29% against (59% of the company cast a for/against vote).
The 40 asset managers below cast 2% of the shares they voted on this item FOR (260,283 for, 11,629,658 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,143 | 4,470,177 | 1 | 0 | Against |
| Fidelity | 0 | 1,875,742 | 0 | 0 | Against |
| BlackRock | 0 | 1,461,890 | 0 | 0 | Against |
| Charles Schwab | 0 | 1,158,081 | 0 | 0 | Against |
| Delaware/Macquarie | 0 | 900,000 | 0 | 0 | Against |
| BRIDGEWAY FUNDS INC | 0 | 441,000 | 0 | 0 | Against |
| Simplify Exchange Traded Funds | 253,140 | 0 | 0 | 0 | For |
| Invesco | 0 | 241,418 | 0 | 0 | Against |
| Equitable | 0 | 222,302 | 0 | 0 | Against |
| AQR | 0 | 126,537 | 0 | 0 | Against |
| Goldman Sachs | 0 | 111,017 | 0 | 0 | Against |
| TIAA | 0 | 95,235 | 0 | 0 | Against |
| Lincoln Financial | 0 | 76,805 | 0 | 0 | Against |
| Northern Trust | 0 | 63,646 | 0 | 0 | Against |
| Global X | 0 | 48,708 | 0 | 0 | Against |
| Bridge Builder Trust | 0 | 41,829 | 0 | 0 | Against |
| Pacific Life | 0 | 40,030 | 0 | 0 | Against |
| Brighthouse | 0 | 34,326 | 0 | 0 | Against |
| QUANTITATIVE MASTER SERIES LLC | 0 | 31,660 | 0 | 0 | Against |
| John Hancock | 0 | 24,919 | 0 | 0 | Against |
| ProShares | 0 | 21,717 | 0 | 0 | Against |
| Voya | 0 | 16,971 | 0 | 0 | Against |
| DWS | 0 | 15,322 | 0 | 0 | Against |
| SEI | 0 | 14,800 | 0 | 0 | Against |
| AIG/SunAmerica | 0 | 14,195 | 0 | 0 | Against |
Showing the 25 largest of 40 asset managers. See all 40 in the interactive database.
Ranked by the number of Coherus Oncology, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 154,249,900 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Janus Henderson | 11.11% |
| 2 | Vanguard | 3.36% |
| 3 | BlackRock | 2.26% |
| 4 | Kohlberg Kravis Roberts & Co. L.P. | 1.97% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 1.52% |
| 6 | Charles Schwab | 1.50% |
| 7 | C WorldWide Asset Management Fondsmaeglerselskab A/S | 1.25% |
| 8 | Fidelity | 1.22% |
| 9 | Samsara BioCapital, LLC | 1.11% |
| 10 | State Street | 0.75% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| BlackRock | 6.72% | 13F |
| Vanguard Group | 6.50% | 13F |
| Timothy G. Youngquist 2020 Irrevocable Trust | 5.09% | DEF14A |
| Thomas A. Satterfield, Jr. | 4.49% | 13G |
| Geode Capital | 2.02% | 13F |
| Ali J. Satvat | 1.97% | DEF14A |
| State Street | 1.51% | 13F |
| Two Sigma | 1.49% | 13F |
| Dennis M. Lanfear | 1.02% | DEF14A |
| AQR Capital | 0.78% | 13F |
Percentages above are of 154,249,900 shares outstanding, as reported by Coherus Oncology, Inc. on its Form 10-Q dated 2026-04-30 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Coherus Oncology, Inc.’s 10-Q dated 2026-04-30. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.
At Coherus Oncology, Inc.'s shareholder meeting held 2026-05-29, in the 2025-2026 proxy season, 127 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 823 separate fund positions. On the most widely held item on that ballot — To vote on a non-binding, advisory basis to approve the compensation of the Company's named… — FOR was 87% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Coherus Oncology, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-01.
Coherus Oncology, Inc. proxy season coverage: 2025-2026 (this page).